西黄丸联合TP方案治疗中晚期乳腺癌效果分析  

Effect of Xihuang Pill Combined with TP Regimen in Treatment of Advanced Breast Cancer

作　　者：千维娜 李治[2] 李仁廷 赵艳莉 肖海娟 司海龙[1,3] 陈晓虹 方瑜[2,3] 吴昭利 QIAN Weina;LI Zhi;LI Renting;ZHAO Yanli;XIAO Haijuan;SI Hailong;CHEN Xiaohong;FANG Yu;WU Zhaoli(Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang 712000,Shaanxi,China;Shaanxi University of Traditional Chinese Medicine,Xianyang 712046,Shaanxi,China;Yiqi Jianpi Method for Prevention and Treatment of Digestive Tumor Neoplasms,Shaanxi University of Traditional Chinese Medicine,Xianyang 712000,Shaanxi,China)

机构地区：[1]陕西中医药大学附属医院,陕西咸阳712000 [2]陕西中医药大学,陕西咸阳712046 [3]陕西中医药大学益气健脾法防治消化系肿瘤创新团队,陕西咸阳712000

出　　处：《辽宁中医杂志》2020年第6期115-117,共3页Liaoning Journal of Traditional Chinese Medicine

基　　金：陕西中医药大学学科创新团队项目(2019-YL06);陕西省第三届名中医传承工作室建设项目(2019003);国家自然科学基金(81704066)。

摘　　要：目的探讨西黄丸联合TP方案治疗中晚期乳腺癌效果。方法选择本院于2014年1月—2015年2月收治的90例中晚期乳腺癌患者,在随机数字表法下分为西黄丸辅助组与TP化疗方案组,每组45例。TP化疗方案组给予TP化疗方案治疗,第一天给予紫杉醇注射液静脉滴注,剂量150 mg/m^2,第2~4天给予顺铂静脉滴注,剂量25 mg/m^2,每天1次。3周作为1个化疗周期,治疗4个化疗周期。西黄丸辅助组在TP化疗方案组治疗基础上联合西黄丸治疗,每次服用3 g,每天2次,治疗12周。对比两组疗效、治疗前后Kamofsky评分、乳腺癌患者生存质量测定量表(FACT-B)评分、糖类抗原125(CA125)、癌胚抗原(CEA)、糖类抗原153(CA153);TP化疗方案不良反应。结果西黄丸辅助组治疗总有效率高于TP化疗方案组(P<0.05);西黄丸辅助组中晚期乳腺癌患者KAMOFSKY评分、乳腺癌患者生存质量测定量表(FACT-B)评分高于TP化疗方案组,而糖类抗原125(CA125)、癌胚抗原(CEA)、糖类抗原153(CA153)低于TP化疗方案组(P<0.05),差异具有统计学意义。西黄丸辅助组中晚期乳腺癌患者TP化疗方案不良反应少于TP化疗方案组(P<0.05),差异具有统计学意义。结论西黄丸联合TP化疗方案治疗乳腺癌的临床疗效确切,可更好改善中晚期乳腺癌患者的生存质量,改善患者的血清肿瘤标志物水平,减少TP化疗方案不良反应。Objective To investigate the effect of Xihuang Pill combined with TP regimen in the treatment of advanced breast cancer.Methods Ninety patients with advanced breast cancer admitted to our hospital from January 2014 to February 2015 were divided into Xihuang Pill adjuvant group and TP chemotherapy group with 45 cases in each group.TP chemotherapy regimen group was treated with TP chemotherapy regimen.Paclitaxel injection was given intravenously on the first day at a dose of 150 mg/m^2.Cisplatin was given intravenously from the second day to the fourth day at a dose of 25 mg/m^2 once a day.Three weeks was as a chemotherapy cycle and totally four chemotherapy cycles were treated.Xihuang Pill adjuvant group was treated with Xihuang Pill on the basis of TP chemotherapy regimen group,taking 3 g each time,twice a day for 12 weeks.The efficacy,Kamofsky score before and after treatment,FACT-B score,carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153),toxicity and side effects of TP chemotherapy were compared between the two groups.Results The total effective rate of Xihuang Pill adjuvant group was higher than that of TP chemotherapy group(P<0.05).KAMOFSKY score and FACT-B score of patients with advanced breast cancer in Xihuang Pill adjuvant group were higher than those of TP chemotherapy group,while carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA) and carbohydrate antigen 153(CA153) were lower than those of TP chemotherapy group(P<0.05),and the difference was statistically significant.The toxicity and side effects of TP chemotherapy regimen in the Xihuang Pill adjuvant group were less than those in the TP chemotherapy regimen group(P <0.05),and the difference was statistically significant.Conclusion Xihuang Pill combined with TP chemotherapy is effective in the treatment of breast cancer.It can improve the quality of life of patients with advanced breast cancer,improve the levels of serum tumor markers,and reduce the toxicity and side effects of TP chemotherapy.

关 键 词：西黄丸 TP方案治疗 中晚期乳腺癌 效果 

分 类 号：R737.9[医药卫生—肿瘤]